The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

This study (SAPPHO) tests a sequential treatment strategy aiming to cure de novo (newly diagnosed) HER2-positive metastatic breast cancer. After initial standard treatment, patients who respond well are given additional targeted therapies in sequence with the goal of achieving long-term remission or cure. **You may be eligible if...** - You are 18 or older with a new (de novo) diagnosis of metastatic breast cancer that is HER2-positive (3+ by IHC on both breast and metastatic biopsies) - You have not had prior treatment for metastatic breast cancer (or have just started standard first-line HER2 therapy — trastuzumab/pertuzumab/taxane — within 6 weeks) - Your heart pumping function (LVEF) is 50% or higher - You are in good general health (ECOG performance status 0–1) - You have adequate blood counts and organ function **You may NOT be eligible if...** - Your HER2 status is 1+ or 2+ (only truly HER2-positive 3+ patients qualify) - You have had prior systemic therapy for invasive breast cancer beyond what is specified above - You are under 18 years old - You have active brain metastases causing symptoms - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.